Women with preterm premature rupture of the membranes do not benefit from weekly progesterone

Christian M. Briery, Edward W. Veillon, Chad K. Klauser, Rick W. Martin, Everett F. Magann, Suneet P. Chauhan, John C. Morrison

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


OBJECTIVE: We sought to determine if 17-alpha-hydroxyprogesterone (17P) extends gestation vs placebo in women with preterm premature rupture of the membranes (PPROM). STUDY DESIGN: Women with vertex presentations with PPROM, 20-30 weeks' gestation, were randomized to receive weekly 17P or placebo in an attempt to prolong the pregnancy. A total of 69 patients (17P, n = 33; placebo, n = 36) were randomized into this study. RESULTS: Initial cervical dilatation, gestational age at enrollment, and interval to delivery were not different between the 2 groups (P = .914, .424, and .146, respectively). Time of randomization to delivery (P = .250), mode of delivery (relative risk, 1.16; 95% confidence interval, 0.662.06), and the neonatal outcome statistics of morbidity (P = .820) and mortality (relative risk, 1.28; 95% confidence interval, 0.592.75) were similar between the 2 groups. CONCLUSION: In patients with PPROM, 17P did not extend gestation vs placebo and cannot be recommended for treatment in such women.

Original languageEnglish
Pages (from-to)54.e1-54.e5
JournalAmerican Journal of Obstetrics and Gynecology
Issue number1
StatePublished - Jan 2011


  • pregnancy prolongation
  • preterm premature rupture of membranes
  • progesterone


Dive into the research topics of 'Women with preterm premature rupture of the membranes do not benefit from weekly progesterone'. Together they form a unique fingerprint.

Cite this